Latest diabetic neuropathy Stories
RICHMOND, Calif., April 26, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today reported first quarter 2011 financial results and accomplishments.
Drugs already in development to treat Alzheimer's disease may eventually be tapped for a different purpose altogether: re-growing the ends of injured nerves to relieve pain and paralysis.
The American Academy of Neurology has issued a new guideline on the most effective treatments for diabetic nerve pain -- the burning or tingling pain in the hands and feet that affects millions of people with diabetes.
BRIDGEWATER, N.J. and TORONTO, Feb.
Gilad&Gilad LLC of Reseda (Los Angeles), California, has re-launched Neurofencine(TM), a first-of-its-kind nutraceutical supplement clinically proven for nerve resilience and pain-free nerve functions.
RICHMOND, Calif., Feb. 2, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today reported fourth quarter and full year 2010 financial results and accomplishments.
Researchers have proved that a single "master switch" enzyme, known as aldose reductase, is key in producing excess mucous that clogs the airways of people with asthma and chronic obstructive pulmonary disease (COPD).
RICHMOND, Calif., Jan. 10, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that the company completed enrollment of its Phase 2b double-blind, placebo-controlled clinical trial (SB-509-901) in subjects with diabetic neuropathy (DN).
RICHMOND, Calif., Nov. 17, 2010 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc.
Celebrating Ground-Breaking Alpha Lipoic Acid Discovery Alpha lipoic acid is a remarkable natural substance, with surprisingly diverse and beneficial properties, but diminished by the poor solubility of raw material crystalline alpha lipoic acid powder used in most oral formulations.